Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock

Published 27/02/2025, 18:42
Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock

SAN FRANCISCO—Vanina de Verneuil, Executive Vice President and General Counsel at Vir Biotechnology, Inc. (NASDAQ:VIR), recently sold 7,373 shares of the company’s common stock. The sales, disclosed in a Form 4 filing with the Securities and Exchange Commission, were conducted on February 26, 2025, and amounted to a total value of $67,402. The shares were sold at a weighted average price of $9.1418, with individual transaction prices ranging from $9.03 to $9.30. The $1.19 billion market cap biotech company has shown strong momentum this year, with shares up over 25% year-to-date according to InvestingPro data.

Following these transactions, de Verneuil holds 79,460 shares directly. The sales were made under a pre-established Rule 10b5-1 trading plan adopted on August 5, 2024. InvestingPro analysis suggests the stock is currently undervalued, with 8 additional key insights available to subscribers. Access the comprehensive Pro Research Report covering VIR and 1,400+ other US stocks to make more informed investment decisions.

In other recent news, Vir Biotechnology Inc . reported its fourth-quarter 2024 earnings, surpassing market expectations with a narrower-than-anticipated loss and significantly higher revenue. The company posted an earnings per share (EPS) of -$0.76, beating the forecasted -$0.87, while revenue reached $12.37 million, exceeding the expected $8.14 million. Vir Biotech has also made notable strides in cost management, with research and development expenses drastically reduced to $57 million from $580 million in 2023, and general and administrative expenses down by 32% to $119 million. Additionally, Vir Biotech is accelerating its ECLIPSE Phase 3 program for hepatitis delta and advancing its PSMA-targeted T cell engager program. The company aims to initiate a Phase 1 study for its EGFR-targeted therapy and seek partnerships for its hepatitis B program. These recent developments reflect the company’s strategic focus on high-potential programs and effective cost management.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.